About Molecular Information Systems
A molecular information system is often used to determine the sequence in DNA or genetic material, enzymes, proteins at the molecular level using kits, reagents, and instruments. Various methods are used to determine the sequence in molecular information, including the use of instruments such as PCR, RAPD, and DNA microarrays. Molecular information systems are beneficial in a variety of medical strengths including infectious diseases, oncology, human leukocyte antigens typing and coagulation, and pharmacogenomics. The impact of COVID-19 on digital solutions in terms of healthcare delivery has been and is very high and accelerating as fast as COVID-19 moves around the world. There are many lessons to be learned from the use of technology in public health monitoring, from linking data in Sentinel laboratories to developing technological solutions to instantly link tests in different geographic locations.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
CAGR | 4.1% |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Molecular Information Systems market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.
Abbott Laboratories (United States), Agilent Technologies Inc. (United States), Biomerieux SA (France), Becton, Dickinson, and Company (United States), Danaher Corporation (United States), F.Hoffmann-La Roche (Switzerland), Hologic Inc. (United States), Siemens Healthineers AG (Germany), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (United States), DiaSorin S.p.A. (Italy) and Luminex Corporation (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Molbio Diagnostics Pvt. Ltd. (India) and geneOmbio Technologies Pvt. Ltd. (India).
Segmentation Overview
AMA Research has segmented the market of Global Molecular Information Systems market by Type (Reagents & Kits, Software & Service and Instruments [Table-top Instruments, Portable & PoC Instruments]), Application (Oncology, Infectious Disease [COVID-19, Hepatitis, HIV, CT/NG, HAI, HPV, Tuberculosis, Influenza, Other], Genetic Tests, Oncology Testing [Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Other] and Others) and Region.
On the basis of geography, the market of Molecular Information Systems has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Technology, the sub-segment i.e. Polymerase Chain Reaction (PCR) will boost the Molecular Information Systems market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Hospital & Academic Laboratories will boost the Molecular Information Systems market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Influencing Trend:
Increasing Demand for Point-Of-Care Diagnostics
Market Growth Drivers:
Increase in Awareness and Acceptance of Personalized Medicine and Companion Diagnostics and High Prevalence of Infectious Diseases and Various Types of Cancers
Challenges:
Delay in Approval of New Molecular Information
Restraints:
Strict Regulatory and Legal Requirements Related To the System and Need For high-complexity Testing Centers
Opportunities:
The Growing Advances in Genomics and Proteomics and Rising Usage of Well-Established Technologies, Such As Immunoassays
Market Leaders and their expansionary development strategies
In January 2023, ConcertAI, the leading oncology real-world evidence data and AI technology company, and Caris Life Sciences®(Caris), the leading molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced a unique partnership to align the two companies’ oncology capabilities. The collaboration creates one of the largest translational and clinical development research platforms aimed at supporting and accelerating biopharmaceutical drug development and novel therapeutic research.
In November 2023, Roche announced today the launch of the LightCycler® PRO System based on the proven gold standard technology of the LightCycler® Systems that came before it. This new system raises the bar for performance and usability while bridging the gap between translational research and in-vitro diagnostics. The LightCycler PRO System further complements Roche's molecular PCR testing portfolio which includes solutions for a variety of healthcare professionals - from those performing research, to those testing patients for cancer, infectious diseases, and other public health challenges.
The FDA has emphasized that it has regulatory authority over LDTs (laboratory-developed tests) but has chosen to exercise some enforcement discretion on such tests. In recent years, however, the FDA has stated that additional monitoring of LDTs is required and that the agency plans to issue a guidance document on it. Even issuing the draft directive will therefore certainly raise questions and create new problems.
Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Providers of Molecular Information Systems, Venture Capitalists and Private Equity Firms and End-Use Industry
About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.